HDRA data

AntiCancer was to present data from two clinical trials of its HDRA assay to optimize cancer treatment at the American Society of Clinical Oncology meeting in Philadelphia this week. The assay tests a portion of a patient's tumor removed during surgery or biopsy. The tumor is grown in a test tube at AntiCancer's laboratory and treated with chemotherapeutics to assess the effectiveness of different drugs. Results, which take 72 hours, are faxed back to the oncologist.

In one study, 128 patients with gastric cancer were tested in a blinded study after resection of the primary lesion. The overall and disease-free survival rates of the HDRA "sensitive" group were significantly higher than those of the HDRA "insensitive" group (p<0.0006 and p<0.0053, respectively). ...